Protalix is a publicly traded biotechnology company (NYSE Amex: PLX), that is producing recombinant therapeutic proteins through the ProCellEx™ plant cell system.

Analyst Coverage
Canaccord Adams Ritu S. Baral
Hapoalim Securities USA, Inc. Raghuram Selvaraju
Oppenheimer Brian Abrahams
UBS Research Jeff Elliott
WBB Securities Daniel T. Mallin

The analysts listed follow Protalix Biotherapuetics Inc. We are providing this list as a service and not as an endorsement or adoption of the information provided by these analysts. Any opinions or estimates regarding the performance of Protalix made by these analysts are theirs and do not represent the opinions of Protalix. We are not responsible for information provided in analyst reports, including inaccuracies they may contain. Some of the analysts firms may be market-makers in Protalix stock and/or hold other long or short positions in the stock, and may provide services to Protalix for which they are compensated.


© 2007 Protalix Biotherapeutics. All Rights Reserved.